机器人放射治疗市场机会、成长动力、产业趋势分析及 2025 - 2034 年预测

2024年，全球机器人放射治疗市场规模达12亿美元，预计年复合成长率将达11.6%，到2024年将达到37亿美元，这得益于各类肿瘤和癌症对精准放射治疗的日益依赖。机器人放射治疗能够提高标靶精准度，进而改善治疗效果并减少疗程。随着对非侵入性和门诊癌症治疗的需求不断增长，机器人系统因其无需手术或住院即可提供高剂量放射治疗的能力而日益受到青睐。这反映出肿瘤治疗途径正朝着价值导向护理和更短復健期的方向发展。

即时影像、运动补偿和人工智慧规划软体的前沿进展进一步推动了机器人放射治疗技术的普及。这些系统可根据患者本身的运动或肿瘤转移自动调整放射治疗剂量，以达到一致、精准的剂量控制。医疗机构更倾向于使用机器人设备来治疗位于精细解剖区域的肿瘤，而不会损害附近的健康组织。追求更少的治疗疗程（即所谓的低分割治疗）也推动了这些系统的普及。因此，越来越多的医护人员和患者选择结合即时监测、光束调製和智慧影像引导治疗的机器人平台。

2024年，机器人放射治疗市场中的放射治疗系统占了56.2%的份额。其先进的标靶能力，提供亚毫米级的精度，已成为治疗重要器官附近或难以触及区域的肿瘤不可或缺的工具。透过显着减少对周围健康组织的辐射暴露，这些系统改变了临床医生处理复杂癌症病例的方式。它们与肿瘤学实践的整合提高了患者的治疗效果和安全性，巩固了其作为下一代癌症治疗标准的地位。

同时，直线加速器 (LINAC) 细分市场在 2024 年创造了 5.122 亿美元的市场规模。这些机器人驱动的设备支援影像导引和调强放射治疗，可根据肿瘤的动态位置提供高度适形的剂量。其自适应计划功能对于肺部或肝臟等移动器官中的肿瘤尤其有用，因为这些器官中的肿瘤会因呼吸或消化而频繁移动。此外，LINAC 在门诊癌症治疗的应用也日益增多，这使得治疗时间更短、更便捷，从而最大限度地减少住院时间并提高患者舒适度。

美国机器人放射治疗市场在2024年创收5.083亿美元，预计2034年将成长至15亿美元。癌症盛行率的上升，尤其是在老年人口中，加剧了对精准高效治疗方案的需求。医院和癌症中心正在增加对机器人平台的投资，以提供恢復时间更短、併发症更少的非侵入性治疗。这种以患者为中心的转变，更倾向于个人化和有针对性的放射治疗，持续推动全球技术的应用。

全球机器人放射治疗市场的主要参与者优先考虑创新、策略合作和地理扩张，以巩固其市场地位。 Accuray 和 Elekta 正在大力投资以人工智慧为基础的治疗计划和自适应治疗系统。西门子医疗和通用电气医疗正在推动整合影像和机器人平台，以提高精准度。 RefleXion 和 ViewRay 正在利用即时肿瘤追踪来差异化其产品。瓦里安、Brainlab 和日立继续增强软体驱动功能，并在新兴市场获得监管部门的批准。联合影像和 ZAP 正在扩大生产规模以满足全球日益增长的需求，三菱电机和 Mevion 则专注于经济实惠和紧凑的系统设计，以开拓中端医疗保健市场。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 全球癌症发生率不断上升
    • 非侵入性和门诊治疗方法的偏好日益增长
    • 成像和运动追踪技术的进步
    • 医疗投资和政府对肿瘤治疗基础设施的资助不断增加
  • 产业陷阱与挑战
    • 机器人放射治疗系统和维护成本高昂
    • 缺乏熟练的专业人员来操作先进的机器人系统
• 成长潜力分析
• 川普政府关税
  • 对贸易的影响
    • 贸易量中断
    • 报復措施
  • 对产业的影响
    • 供应方影响（原料）
      • 主要材料价格波动
      • 供应链重组
      • 生产成本影响
    • 需求面影响（售价）
      • 价格传导至终端市场
      • 市占率动态
      • 消费者反应模式
  • 受影响的主要公司
  • 策略产业反应
    • 供应链重组
    • 定价和产品策略
    • 政策参与
  • 展望与未来考虑
• 技术格局
• 未来市场趋势
• 监管格局
• 专利分析
• 差距分析
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 竞争市占率分析
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略展望矩阵

第五章：市场估计与预测：按产品，2021 年至 2034 年

• 主要趋势
• 放射治疗系统
• 3D相机
• 软体
• 其他产品

第六章：市场估计与预测：按技术，2021 年至 2034 年

• 主要趋势
• 直线加速器
• 立体定位放射治疗系统
• 射波刀
• 伽玛刀
• 粒子治疗
• 质子束治疗
• 重离子束治疗

第七章：市场估计与预测：按应用，2021 年至 2034 年

• 主要趋势
• 摄护腺癌
• 乳癌
• 肺癌
• 头颈癌
• 大肠直肠癌
• 其他应用

第八章：市场估计与预测：依最终用途，2021 年至 2034 年

• 主要趋势
• 医院
• 癌症治疗中心
• 学术和研究机构
• 专科诊所

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 日本
  • 中国
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第十章：公司简介

• Accuray
• Brainlab
• Elekta
• GE Healthcare
• Hitachi
• Ion Beam Applications
• Mevion
• Mitsubishi Electric
• RefleXion
• Shinva
• Siemens Healthineers
• United Imaging
• Varian
• ViewRay
• ZAP

The Global Robotic Radiotherapy Market was valued at USD 1.2 billion in 2024 and is estimated to grow at a CAGR of 11.6% to reach USD 3.7 billion by 2024, driven by the increasing reliance on precision-driven radiation therapies for various tumors and cancers. Robotic radiotherapy enables enhanced targeting accuracy, leading to better treatment outcomes and reduced therapy sessions. As demand for non-invasive and outpatient cancer treatments grows, robotic systems are gaining favor for their ability to deliver high-dose radiation without the need for surgery or hospitalization. This reflects a broader shift toward value-based care and shorter recovery periods in oncology treatment pathways.

Cutting-edge advances in real-time imaging, motion compensation, and AI-powered planning software are further fueling the adoption of robotic radiotherapy technologies. These systems automatically adapt radiation delivery to patient-specific movement or tumor shifts, enabling consistent, accurate dosing. Facilities prefer robotic equipment to treat tumors in delicate anatomical regions without harming nearby healthy tissue. The push for fewer treatment sessions, known as hypofractionation, is also contributing to the popularity of these systems. As a result, both healthcare providers and patients are increasingly opting for robotic platforms that combine real-time monitoring, beam modulation, and smart image-guided therapy.

In 2024, the radiotherapy systems segment in the robotic radiotherapy market held a 56.2% share. Their advanced targeting capabilities, offering sub-millimeter precision, have become indispensable in treating tumors located near vital organs or in hard-to-reach areas. By significantly reducing radiation exposure to surrounding healthy tissue, these systems have transformed the way clinicians manage complex cancer cases. Their integration into oncology practices has elevated patient outcomes and safety profiles, solidifying their role as a standard in next-generation cancer treatment.

Meanwhile, linear accelerators (LINACs) segment generated USD 512.2 million in 2024. These robotic-enabled devices support image-guided and intensity-modulated radiotherapy, delivering highly conformal doses tailored to dynamic tumor positions. Their adaptive planning features are especially valuable for tumors in mobile organs such as the lungs or liver, where breathing or digestion introduces frequent positional shifts. Additionally, LINACs are increasingly utilized in outpatient cancer care, allowing for shorter, more convenient treatment sessions that minimize hospital stays and maximize patient comfort.

U.S. Robotic Radiotherapy Market generated USD 508.3 million in 2024 and is projected to grow to USD 1.5 billion by 2034. Rising cancer prevalence-especially in an aging population-has intensified the need for precise, efficient treatment solutions. Hospitals and cancer centers are expanding investments in robotic platforms to offer non-invasive therapies with reduced recovery times and fewer complications. This patient-centric shift, favoring customized and targeted radiation approaches, continues to fuel technology adoption worldwide.

Key players in the Global Robotic Radiotherapy Market prioritize innovation, strategic collaborations, and geographic expansion to solidify their market standing. Accuray and Elekta are investing heavily in AI-based treatment planning and adaptive therapy systems. Siemens Healthineers and GE Healthcare are advancing integrated imaging and robotic platforms to boost precision. RefleXion and ViewRay are leveraging real-time tumor tracking to differentiate their offerings. Varian, Brainlab, and Hitachi continue to enhance software-driven functionalities and secure regulatory approvals in emerging markets. United Imaging and ZAP are scaling up production to meet growing demand globally, Mitsubishi Electric and Mevion focus on affordability and compact system design to tap mid-tier healthcare segments.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of cancer worldwide
    • 3.2.1.2 Growing preference for non-invasive and outpatient treatment methods
    • 3.2.1.3 Technological advancements in imaging and motion tracking
    • 3.2.1.4 Rising healthcare investments and government funding in oncology care infrastructure
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High cost of robotic radiotherapy systems and maintenance
    • 3.2.2.2 Lack of skilled professionals to operate advanced robotic systems
• 3.3 Growth potential analysis
• 3.4 Trump administration tariffs
  • 3.4.1 Impact on trade
    • 3.4.1.1 Trade volume disruptions
    • 3.4.1.2 Retaliatory measures
  • 3.4.2 Impact on the Industry
    • 3.4.2.1 Supply-side impact (raw materials)
      • 3.4.2.1.1 Price volatility in key materials
      • 3.4.2.1.2 Supply chain restructuring
      • 3.4.2.1.3 Production cost implications
    • 3.4.2.2 Demand-side impact (selling price)
      • 3.4.2.2.1 Price transmission to end markets
      • 3.4.2.2.2 Market share dynamics
      • 3.4.2.2.3 Consumer response patterns
  • 3.4.3 Key companies impacted
  • 3.4.4 Strategic industry responses
    • 3.4.4.1 Supply chain reconfiguration
    • 3.4.4.2 Pricing and product strategies
    • 3.4.4.3 Policy engagement
  • 3.4.5 Outlook and future considerations
• 3.5 Technology landscape
• 3.6 Future market trends
• 3.7 Regulatory landscape
• 3.8 Patent analysis
• 3.9 Gap analysis
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Competitive market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategic outlook matrix

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Radiotherapy systems
• 5.3 3D cameras
• 5.4 Software
• 5.5 Other products

Chapter 6 Market Estimates and Forecast, By Technology, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Linear accelerators
• 6.3 Stereotactic radiation therapy systems
• 6.4 Cyberknife
• 6.5 Gamma knife
• 6.6 Particle therapy
• 6.7 Proton beam therapy
• 6.8 Heavy ion beam therapy

Chapter 7 Market Estimates and Forecast, By Application, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Prostate cancer
• 7.3 Breast cancer
• 7.4 Lung cancer
• 7.5 Head and neck cancer
• 7.6 Colorectal cancer
• 7.7 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Cancer treatment centers
• 8.4 Academic and research institutions
• 8.5 Specialty clinics

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Italy
  • 9.3.5 Spain
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Mexico
  • 9.5.2 Brazil
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Accuray
• 10.2 Brainlab
• 10.3 Elekta
• 10.4 GE Healthcare
• 10.5 Hitachi
• 10.6 Ion Beam Applications
• 10.7 Mevion
• 10.8 Mitsubishi Electric
• 10.9 RefleXion
• 10.10 Shinva
• 10.11 Siemens Healthineers
• 10.12 United Imaging
• 10.13 Varian
• 10.14 ViewRay
• 10.15 ZAP